contentSlug

type

ContentSlug_ContentQuery

slug

ContentPageContentQuery

content

trendingContent

query ContentSlug_ContentQuery(
  $contentSlug: String!
  $type: [ContentType!]
) {
  ...ContentPageContentQuery_13QmVO
}

fragment CompanyDetails_Content on Content {
  __isContent: __typename
  companies {
    name
    description
    pageUrl
    id
  }
}

fragment ContentBasicInfo on Content {
  __isContent: __typename
  id
  type
  title
  lang
  companies {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  tags {
    viewerIsFollowing
    id
    name
    pageUrl
  }
  ...PublishingDetails
  ...Reactions
}

fragment ContentMetadata on Content {
  __isContent: __typename
  type
  title
  lang
  pageUrl
  alternatePageUrls: translations {
    __typename
    pageUrl
    lang
  }
  imgUrl
  description
  ... on Video {
    liveTime
    videoUrl
  }
  ... on Webcast {
    liveTime
    videoUrl
  }
}

fragment ContentPageContentQuery_13QmVO on Query {
  content(slug: $contentSlug, type: $type) {
    __typename
    id
    type
    title
    isPremium
    lang
    htmlBody
    summary
    companies {
      forum {
        latestPosts {
          ...ForumPosts
        }
      }
      name
      id
      viewerIsFollowing
      pageUrl
      defaultInstrument {
        isin
        id
        marketOpen
        marketClose
        marketplace {
          region
        }
        returns {
          total
        }
      }
    }
    tags {
      viewerIsFollowing
      id
      name
      pageUrl
    }
    createdAt
    ... on Video {
      liveTime
    }
    ... on Webcast {
      liveTime
    }
    slug
    ... on CompanyReport {
      reportUrl
    }
    ... on ThirdPartyCompanyReport {
      reportUrl
    }
    ... on StockExchangeRelease {
      reportUrl
    }
    ...ContentBasicInfo
    ...ContentMetadata
    ...PriceAndRecommendation_Content
    ...CompanyDetails_Content
    ...ReportLink_Content
    ...KeyFigures_Content
  }
  ...TrendingContent_1jQ2Cn
}

fragment ForumPosts on ForumPost {
  text
  likesCount
  url
  author
  postedAt
  authorImgUrl
}

fragment KeyFigures_Content on Content {
  __isContent: __typename
  companies {
    defaultInstrument {
      estimateData {
        modelType
        reportingCurrency
      }
      snapshot {
        transaction {
          date
          actualized {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
          estimates {
            year
            quarter
            revenue
            revenueGrowth
            ebitAdjusted
            ebitReported
            ebitda
            enterpriseValue
            epsAdjusted
            dividend
            dividendYield
            sharePrice
          }
        }
      }
      id
    }
    id
  }
}

fragment PriceAndRecommendation_Content on Content {
  __isContent: __typename
  createdAt
  companies {
    name
    pageUrl
    defaultInstrument {
      priceData {
        tradeCurrency
      }
      snapshot {
        priceData {
          date
          lastPrice
          tradeCurrency
        }
        transaction {
          date
          recommendation
          targetPrice
        }
        prevTransaction {
          recommendation
        }
      }
      id
    }
    id
  }
}

fragment PublishingDetails on Content {
  __isContent: __typename
  createdAt
  publishers {
    name
    imgUrl
  }
  authors {
    __typename
    id
    name
    slug
    imgUrl
    jobTitle
  }
  ... on Video {
    liveTime
  }
  ... on Webcast {
    liveTime
  }
}

fragment Reactions on Content {
  __isContent: __typename
  id
  reactionGroups {
    reactionType
    reactionsCount
    viewerReacted
  }
}

fragment ReportLink_Content on Content {
  __isContent: __typename
  type
  isPremium
  ... on CompanyReport {
    reportUrl
  }
  ... on ThirdPartyCompanyReport {
    reportUrl
  }
  ... on StockExchangeRelease {
    reportUrl
  }
}

fragment TrendingContent_1jQ2Cn on Query {
  trendingContent(type: ARTICLE) {
    __typename
    id
    title
    lang
    pageUrl
    createdAt
    type
    imgUrl
    companies {
      squareLogoUrl
      name
      id
    }
    authors {
      __typename
      imgUrl
      id
    }
    publishers {
      imgUrl
    }
  }
}


bio-works-technologies-ab-strong-interest-in-workbeadstm-affimab-edge-next-generation-protein-a-resin-for-antibody-purification

__typename

title

isPremium

lang

htmlBody

summary

companies

createdAt

publishers

authors

reactionGroups

pageUrl

translations

imgUrl

description

Bio-Works Technologies operates in biotechnology. The company develops products that separate and purify molecules in the production of pharmaceuticals. The technology is based on chromatography, which is intended to handle the drug substance. Customers are found in the European market where the products are sold via distribution partners and to companies in the pharmaceutical industry, as well as research institutes and universities. The company was founded in 2006 and has its headquarters in Uppsala.

Bio-Works Technologies

Bio-Works Technologies AB announced on August 19th, 2025, the launch of WorkBeads™ affimAb Edge, a resin with market leading performance designed for efficient purification of monoclonal antibodies...

<div class="abstract">Bio-Works Technologies AB announced on August 19th, 2025, the launch of&nbsp;&nbsp;WorkBeads™ affimAb Edge, a resin with market leading performance designed for efficient purification of monoclonal antibodies and Fc-containing fragments or fusion proteins from laboratory to production scale.</div>Built on an improved macroporous agarose-based matrix and coupled with an alkali-stable recombinant Protein A ligand, WorkBeads affimAb Edge delivers:<ul>	<li>High performance and process economy: Dynamic binding capacities exceeding 70 mg/mL at 6 minutes residence time.</li>	<li>Superior pressure flow properties: Enabling faster cycle times and robust process scalability.</li>	<li>Alkali stability: Supporting repeated cleaning and sanitization with 0.5 M NaOH for extended resin lifetime.</li>	<li>Improved purity: Demonstrated effective removal of host cell proteins (HCP) with consistently low impurity levels across 150+ cycles.</li>	<li>Low ligand leakage: Comparable to leading resins on the market, ensuring reliable downstream results.</li></ul>For the customer this means&nbsp;high productivity and scalability - delivering consistently high purity and yield.The resin is available in bulk and a wide range of convenient prepacked GoBio™ column formats-from small-scale screening to production-scale purification-making it an attractive solution for both process development and commercial manufacturing.Strong Market ResponseSince its introduction, WorkBeads affimAb Edge has already attracted significant attention from the global biopharmaceutical community, with many large biopharma companies actively requesting samples for evaluation. This reflects the industry's need for cost-effective and high-performing alternatives in antibody purification workflows."WorkBeads affimAb Edge represents an important step forward in delivering performance, robustness, and process economy to our customers in biopharma. We are proud to see strong demand from leading global companies so early after launch, which reinforces the market's confidence in our technology," said Lone Carlbom, CEO, Bio-Works Technologies AB.<div></div>

Bio-Works Technologies AB: Strong interest in WorkBeads™ affimAb Edge: Next-Generation Protein A Resin for Antibody Purification